APA (7th ed.) Citation

S, P., M, E., S, N., M, T., E, W., KN, C., . . . BJ, E. (2016). Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational new drugs, 34(6), 771. https://doi.org/10.1007/s10637-016-0386-z

Chicago Style (17th ed.) Citation

S, Parimi, Eliasziw M, North S, Trudeau M, Winquist E, Chi KN, Ruether D, Cheng T, and Eigl BJ. "Sunitinib Maintenance Therapy After Response to Docetaxel in Metastatic Castration Resistant Prostate Cancer (mCRPC)." Investigational New Drugs 34, no. 6 (2016): 771. https://doi.org/10.1007/s10637-016-0386-z.

MLA (9th ed.) Citation

S, Parimi, et al. "Sunitinib Maintenance Therapy After Response to Docetaxel in Metastatic Castration Resistant Prostate Cancer (mCRPC)." Investigational New Drugs, vol. 34, no. 6, 2016, p. 771, https://doi.org/10.1007/s10637-016-0386-z.